339 results on '"Batra, U"'
Search Results
2. Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
3. P1.23-02 Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC
4. EP06.04-02 FLUIDIndia:Liquid "First" Approach is a "Solid" Solution in NSCLC
5. P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR
6. Optimum level of insulation for energy efficient envelope of office buildings
7. MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC.
8. 257MO Integrating AI and ML with lung cancer diagnostics: A step ahead
9. 395P Molecular landscape of Indian NSCLC: Is NGS the answer?
10. 121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
11. 269P MET alterations in EGFR mutated NSCLC: A lesser known evil
12. 267P Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
13. 263MO Variant allele frequency and copy number gain in EGFR mutated lung cancer: A menace or a boon?
14. 357P Molecular stratification of small cell lung carcinoma subtypes by immunoexpression of ASCL1, NEUROD1, POU2F3 and YAP1 with clinicopathological correlation
15. 122P Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
16. 15P KRAS mutation in metastatic non-small cell lung carcinoma (NSCLC): The Indian subcontinent experience from a tertiary cancer center
17. EP16.03-047 Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort
18. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
19. 160P LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients
20. 159P ReWARD study - Real-world ALK-resistance data: A single center experience
21. Investigation of Mechanical and Wear Characteristics of Forged Fe-Al-C Intermetallic Quaternary Alloyed with Zr/Ti
22. P51.07 Small Cell Transformation of Non Small Cell Lung Carcinoma: Tissue Biopsy Is Here to Stay!
23. P59.10 A Sneak Peak in the Future World of EGFR Mutations: ML Based PFS Differences Between Del 19 and L858R
24. P45.02 Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer
25. P07.01 Usage Patterns of TKIs in EGFR Mutant NSCLC: Let's Get REAL
26. P48.03 Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients
27. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients
28. 1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
29. 39P Tissue vs. cobas vs. DDPCR for EGFR in NSCLC: Real-world evidence from India
30. 44P Inter-reader variability of lung parenchymal observations on chest CT among COVID-19 RT-PCR negative lung cancer patients treated with chemo-radiation: Potential pitfalls of pulmonary findings in different readers with various experience levels
31. 5P False positive errors in RNA based next generation sequencing of exon 14 skipping mutations in NSCLC
32. P37.06 Are all ALK Gene Rearrangements Created Equal??
33. P40.04 Knowledge, Attitudes and Perception of Lung Cancer Screening Among Smoking Soft-Ware Professionals in India
34. MA04.06 Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005)
35. P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)
36. Clinical profile of nonsmall cell lung carcinoma patients treated in a single unit at a tertiary cancer care center
37. Role of crizotinib in c-mesenchymal-epidermal transition-positive nonsmall cell lung cancer patients
38. Fracture behavior and mechanism in austempered ductile iron
39. Tensile properties of copper alloyed austempered ductile iron: Effect of austempering parameters
40. The influence of nickel and copper on the austempering of ductile iron
41. 202P Molecular kaleidoscope of EGFR mutant NSCLC: Be as precise as possible
42. 418P All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
43. 215P Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
44. 330P COVID and cancer: Choosing between hammer and anvil
45. Real world evidence of palbociclib use in metastatic hormone positive HER negative metastatic breast cancer in Indian population
46. 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
47. Epidemiology and resistance pattern of bacterial isolates among cancer patients in a Tertiary Care Oncology Centre in North India
48. Epidemiology of ventilator associated pneumonia (vap) in patients with abdominal sepsis
49. NGS in advanced NSCLC in a developing country: Ready for prime time?
50. Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.